proteins Inhibitors
1 drugsAbout proteins
Proteins are a crucial class of drug targets, performing diverse functions in normal physiology and disease. Modulating protein activity with drugs can have significant therapeutic effects, impacting various biological processes.
Currently, there is no genetic evidence available linking protein targets to specific diseases. Despite the lack of genetic data, the presence of an approved drug suggests that modulating protein function can provide clinical benefit.
There is one FDA-approved drug, BICNU, targeting proteins, developed by AVET LIFESCIENCES. BICNU, a small molecule, is used in oncology and was first approved in 1977.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type with only 1 trials.
- phase1 represents biological uncertainty with 58% completion.
Top proteins Drugs
AVET LIFESCIENCES is the only company with an approved drug targeting proteins.
The market is highly concentrated, suggesting high barriers to entry or a lack of investment.
proteins Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets proteins, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage.
proteins Clinical Trials 53 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 10 | 7 | 3 | 59% |
| Phase 2 | 29 | 10 | 8 | 11 | 56% |
| Phase 3 | 4 | 0 | 3 | 1 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
proteins Drug Approval Timeline (1977 - 1977)
The first and only drug, BICNU, was approved in 1977.
The lack of recent approvals indicates potential saturation or challenges in developing new protein-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 40 clinical trials targeting proteins.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities